Association of a Dominant T-Cell Clone in Peripheral Blood With Time to Systemic Treatment in Patients With Stage IB Mycosis Fungoides

Suravi Raychaudhuri(Stanford University), Weiyun Z. Ai(City College of San Francisco), Michelle A. Mintz(University of California, San Francisco), Chiung‐Yu Huang, Laura B. Pincus(University of California, San Francisco), Yann Charli‐Joseph(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán)

JAMA Dermatology

June 22, 2022

10.1001/jamadermatol.2022.2100

Cited by 9

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

|Journal of Clinical Oncology|2010|487

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

|The Lancet Oncology|2021|428

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247